Institute of Medical Research & Technology Assessment (IMRTA) announced collaboration with RxLeaf World Medica Co., Ltd., under International Medical Cannabis Research Center (IMCRC) on developing medicine formulae from cannabis through conducting clinical trials covering eight disease groups.
Ms. Nongluck Kowatana, Chief Executive Officer of RxLeaf World Medica Co., Ltd., revealed that the company signed a contract with Institute of Medical Research & Technology Assessment (IMRTA), Department of Medical Services, Ministry of Public Health, under International Medical Cannabis Research Center (IMCRC) to collaborate on developing cannabis oil under special access scheme and conducting clinical trials covering disease groups and medical conditions including nausea from chemotherapy remedies, epilepsy, drug-resistant epilepsy, demyelinating disease and related conditions including resistant multiple sclerosis (MS) and neuromyelitis optica (NMO), palliative care and cancer patients in palliative care, Parkinson's disease, Alzheimer's disease, and skin disease such as psoriasis and dermatitis.
"Conducting clinical trials with Neurological Institute of Thailand, Institute of Dermatology, and National Cancer Institute will allow Thailand to obtain medicines from planted and extracted cannabis, as well as medicine formulae developed in collaboration with experts across the world, which will enable Thailand to step up as a leader in medical cannabis development on a regional and global scale and generate income to the country according to the national strategy of medical tourism" said Ms. Nongluck Kowatana.